|
1
|
Witchel SF, Recabarren SE, González F,
Diamanti-Kandarakis E, Cheang KI, Duleba AJ, Legro RS, Homburg R,
Pasquali R, Lobo RA, et al: Emerging concepts about prenatal
genesis, aberrant metabolism and treatment paradigms in polycystic
ovary syndrome. Endocrine. 42:526–534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rojas J, Chávez M, Olivar L, Rojas M,
Morillo J, Mejías J, Calvo M and Bermúdez V: Polycystic ovary
syndrome, insulin resistance, and obesity: Navigating the
pathophysiologic labyrinth. Int J Reprod Med. 2014:7190502014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fauser BC, Tarlatzis BC, Rebar RW, Legro
RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS, et
al: Consensus on women's health aspects of polycystic ovary
syndrome (PCOS): The amsterdam ESHRE/ASRM-sponsored 3rd PCOS
consensus workshop group. Fertil Steril. 97:28–38.e25. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan H, Zhu G, Wang F, Wang X, Guo H and
Shen M: Interaction between common variants of FTO and MC4R is
associated with risk of PCOS. Reprod Biol Endocrinol. 13:552015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Goodarzi MO, Dumesic DA, Chazenbalk G and
Azziz R: Polycystic ovary syndrome: Etiology, pathogenesis and
diagnosis. Nat Rev Endocrinol. 7:219–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ollila MM, Piltonen T, Puukka K, Ruokonen
A, Järvelin MR, Tapanainen JS, Franks S and Morin-Papunen L: Weight
gain and dyslipidemia in early adulthood associate with polycystic
ovary syndrome: Prospective cohort study. J Clin Endocrinol Metab.
101:739–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Diamanti-Kandarakis E: Polycystic ovarian
syndrome: Pathophysiology, molecular aspects and clinical
implications. Expert Rev Mol Med. 10:e32008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ni XR, Sun ZJ, Hu GH and Wang RH: High
concentration of insulin promotes apoptosis of primary cultured rat
ovarian granulosa cells via its increase in extracellular HMGB1.
Reprod Sci. 22:271–277. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Velásquez E: Chronic complications of
polycystic ovary syndrome. Review. Invest Clin. 43:205–213.
2002.(In Spanish). PubMed/NCBI
|
|
10
|
Huang Y, Sun J, Wang X, Tao X, Wang H and
Tan W: Asymptomatic chronic gastritis decreases metformin tolerance
in patients with type 2 diabetes. J Clin Pharm Ther. 40:461–465.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ,
Yan B, Wang LY, Yang SY and Zhang SH: Metformin vs.
thiazolidinediones for treatment of clinical, hormonal and
metabolic characteristics of polycystic ovary syndrome: A
meta-analysis. Clin Endocrinol (Oxf). 74:332–339. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cholesterol Treatment Trialists' (CTT)
Collaboration, ; Baigent C, Blackwell L, Emberson J, Holland LE,
Reith C, Bhala N, Peto R, Barnes EH, Keech A, et al: Efficacy and
safety of more intensive lowering of LDL cholesterol: A
meta-analysis of data from 170,000 participants in 26 randomised
trials. Lancet. 376:1670–1681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ji XY, Tan BK and Zhu YZ: Salvia
miltiorrhiza and ischemic diseases. Acta Pharmacol Sin.
21:1089–1094. 2000.PubMed/NCBI
|
|
14
|
Wang X, Morris-Natschke SL and Lee KH: New
developments in the chemistry and biology of the bioactive
constituents of Tanshen. Med Res Rev. 27:133–148. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yu J, Zhai D, Hao L, Zhang D, Bai L, Cai Z
and Yu C: Cryptotanshinone reverses reproductive and metabolic
disturbances in PCOS model rats via regulating the expression of
CYP17 and AR. Evid Based Complement Alternat Med. 2014:6707432014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ong M, Peng J, Jin X and Qu X: Chinese
herbal medicine for the optimal management of polycystic ovary
syndrome. Am J Chin Med. 45:405–422. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang Y, Li W, Wang CC, Wu X and Zheng J:
Cryptotanshinone reverses ovarian insulin resistance in mice
through activation of insulin signaling and the regulation of
glucose transporters and hormone synthesizing enzymes. Fertil
Steril. 102:589–596.e584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jiang B, Xue M, Xu D, Song Y and Zhu S:
Upregulation of microRNA-204 improves insulin resistance of
polycystic ovarian syndrome via inhibition of HMGB1 and the
inactivation of the TLR4/NF-κB pathway. Cell Cycle. 19:697–710.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Zhang Y, Wu X, Bae CS, Hou L,
Kuang H, Wang Y and Stener-Victorin E: Cryptotanshinone reverses
reproductive and metabolic disturbances in prenatally androgenized
rats via regulation of ovarian signaling mechanisms and androgen
synthesis. Am J Physiol Regul Integr Comp Physiol. 300:R869–R875.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Poretsky L, Clemons J and Bogovich K:
Hyperinsulinemia and human chorionic gonadotropin synergistically
promote the growth of ovarian follicular cysts in rats. Metabolism.
41:903–910. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ngo HT, Hetland RB, Sabaredzovic A, Haug
LS and Steffensen IL: In utero exposure to perfluorooctanoate
(PFOA) or perfluorooctane sulfonate (PFOS) did not increase body
weight or intestinal tumorigenesis in multiple intestinal neoplasia
(Min/+) mice. Environ Res. 132:251–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mangano C, Scarano A, Perrotti V, Iezzi G
and Piattelli A: Maxillary sinus augmentation with a porous
synthetic hydroxyapatite and bovine-derived hydroxyapatite: A
comparative clinical and histologic study. Int J Oral Maxillofac
Implants. 22:980–986. 2007.PubMed/NCBI
|
|
23
|
deMoura MD, Chamoun D, Resnick CE and
Adashi EY: Insulin-like growth factor (IGF)-I stimulates IGF-I and
type 1 IGF receptor expression in cultured rat granulosa cells:
Autocrine regulation of the intrafollicular IGF-I system.
Endocrine. 13:103–110. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
March WA, Moore VM, Willson KJ, Phillips
DIW, Norman RJ and Davies MJ: The prevalence of polycystic ovary
syndrome in a community sample assessed under contrasting
diagnostic criteria. Hum Reprod. 25:544–551. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Azziz R, Marin C, Hoq L, Badamgarav E and
Song P: Health care-related economic burden of the polycystic ovary
syndrome during the reproductive life span. J Clin Endocrinol
Metab. 90:4650–4658. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barthelmess EK and Naz RK: Polycystic
ovary syndrome: Current status and future perspective. Front Biosci
(Elite Ed). 6:104–119. 2014.PubMed/NCBI
|
|
28
|
Xia Y, Zhao P, Huang H, Xie Y, Lu R and Li
D: Cryptotanshinone reverses reproductive disturbances in rats with
dehydroepiandrosterone-induced polycystic ovary syndrome. Am J
Transl Res. 9:2447–2456. 2017.PubMed/NCBI
|
|
29
|
Rosenfield RL and Ehrmann DA: The
pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of
PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev.
37:467–520. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nestler JE, Powers LP, Matt DW, Steingold
KA, Plymate SR, Rittmaster RS, Clore JN and Blackard WG: A direct
effect of hyperinsulinemia on serum sex hormone-binding globulin
levels in obese women with the polycystic ovary syndrome. J Clin
Endocrinol Metab. 72:83–89. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shorakae S, Ranasinha S, Abell S, Lambert
G, Lambert E, de Courten B and Teede H: Inter-related effects of
insulin resistance, hyperandrogenism, sympathetic dysfunction and
chronic inflammation in PCOS. Clin Endocrinol (Oxf). 89:628–633.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu M, Gao J, Zhang Y, Li P, Wang H, Ren X
and Li C: Serum levels of TSP-1, NF-κB and TGF-β1 in polycystic
ovarian syndrome (PCOS) patients in northern China suggest PCOS is
associated with chronic inflammation. Clin Endocrinol (Oxf).
83:913–922. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang X, Xue C, Xu Q, Zhang Y, Li H, Li F,
Liu Y and Guo C: Caprylic acid suppresses inflammation via
TLR4/NF-κB signaling and improves atherosclerosis in ApoE-deficient
mice. Nutr Metab (Lond). 16:402019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li G, Wu X, Yang L, He Y, Liu Y, Jin X and
Yuan H: TLR4-mediated NF-κB signaling pathway mediates
HMGB1-induced pancreatic injury in mice with severe acute
pancreatitis. Int J Mol Med. 37:99–107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Osuka K, Watanabe Y, Usuda N, Iwami K,
Miyachi S and Takayasu M: Expression of high mobility group B1 and
toll-like receptor-nuclear factor κB signaling pathway in chronic
subdural hematomas. PLoS One. 15:e02336432020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koc O, Ozdemirici S, Acet M, Soyturk U and
Aydin S: Nuclear factor-κB expression in the endometrium of normal
and overweight women with polycystic ovary syndrome. J Obstet
Gynaecol. 37:924–930. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim SW, Lim CM, Kim JB, Shin JH, Lee S,
Lee M and Lee JK: Extracellular HMGB1 released by NMDA treatment
confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway.
Neurotox Res. 20:159–169. 2011. View Article : Google Scholar : PubMed/NCBI
|
